Affimed (AFMD) Stock Forecast, Price Target & Predictions
AFMD Stock Forecast
Affimed stock forecast is as follows: an average price target of $7.50 (represents a 129.36% upside from AFMD’s last price of $3.27) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AFMD Price Target
AFMD Analyst Ratings
Affimed Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 01, 2024 | Bradley Canino | Stifel Nicolaus | $5.00 | $5.30 | -5.66% | 52.91% |
Apr 01, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $10.00 | $5.30 | 88.68% | 205.81% |
Affimed Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $7.50 |
Last Closing Price | $3.27 | $3.27 | $3.27 |
Upside/Downside | -100.00% | -100.00% | 129.36% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jun 12, 2024 | Laidlaw | Buy | Buy | Hold |
Apr 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Dec 12, 2022 | H.C. Wainwright | - | Buy | Initialise |
Oct 11, 2022 | Stifel Nicolaus | - | Positive | Downgrade |
Mar 31, 2022 | Piper Sandler | - | Overweight | Initialise |
Feb 23, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Affimed Financial Forecast
Affimed Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.51M | $11.16M | $14.89M | $7.30M | $8.01M | $10.34M | $8.66M | $9.71M | $11.66M | $9.75M | $10.54M | $2.93M | $5.13M | $3.93M | $2.10M |
Avg Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $362.75K | $362.75K | $362.75K | $362.75K | $1.63M | $1.67M | $1.16M | $458.57K | $1.66M | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
High Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $362.75K | $362.75K | $362.75K | $362.75K | $1.63M | $2.67M | $1.16M | $458.57K | $2.62M | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
Low Forecast | $151.48K | $151.73K | $151.98K | $152.23K | $362.75K | $362.75K | $362.75K | $362.75K | $1.63M | $663.31K | $1.16M | $458.57K | $643.08K | $1.93M | $4.65M | $6.16M | $6.92M | $6.29M | $8.83M | $10.31M | $8.98M | $9.59M | $9.01M | $10.63M | $16.63M | $8.79M | $5.20M | $5.47M | $3.09M | $3.71M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 8 | 8 | 12 | 7 | 12 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 1.61% | 2.37% | 0.83% | 0.78% | 1.15% | 0.90% | 1.08% | 1.10% | 0.59% | 1.20% | 0.56% | 0.94% | 1.27% | 0.57% |
Affimed EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 8 | 8 | 12 | 7 | 12 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-30.66M | $-27.85M | $-18.73M | $-21.33M | $-16.85M | $-22.51M | $-16.56M | $-18.24M | $1.83M | $-14.66M | $-5.65M | $-11.90M | $-7.95M | $-12.64M | $-10.55M |
Avg Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-362.75K | $-362.75K | $-362.75K | $-362.75K | $-1.63M | $-1.67M | $-1.16M | $-458.57K | $-1.66M | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-10.31M | $-8.98M | $-9.59M | $-9.01M | $3.71M | $-16.63M | $-8.79M | $-5.20M | $-7.95M | $-3.09M | $-3.71M |
High Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-362.75K | $-362.75K | $-362.75K | $-362.75K | $-1.63M | $-663.31K | $-1.16M | $-458.57K | $-643.08K | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-10.31M | $-8.98M | $-9.59M | $-9.01M | $4.45M | $-16.63M | $-8.79M | $-5.20M | $-6.36M | $-3.09M | $-3.71M |
Low Forecast | $-151.48K | $-151.73K | $-151.98K | $-152.23K | $-362.75K | $-362.75K | $-362.75K | $-362.75K | $-1.63M | $-2.67M | $-1.16M | $-458.57K | $-2.62M | $-1.93M | $-4.65M | $-6.16M | $-6.92M | $-6.29M | $-8.83M | $-10.31M | $-8.98M | $-9.59M | $-9.01M | $2.96M | $-16.63M | $-8.79M | $-5.20M | $-9.53M | $-3.09M | $-3.71M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.97% | 4.03% | 2.98% | 2.42% | 1.63% | 2.51% | 1.73% | 2.02% | 0.49% | 0.88% | 0.64% | 2.29% | 1.00% | 4.09% | 2.85% |
Affimed Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 8 | 8 | 12 | 7 | 12 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-31.98M | $-36.73M | $-13.77M | $-17.16M | $-16.66M | $-23.27M | $-17.09M | $-18.75M | $1.41M | $-14.87M | $-5.97M | $-12.24M | $-8.29M | $-12.99M | $-10.88M |
Avg Forecast | $-14.58M | $-14.61M | $-12.70M | $-12.73M | $-11.04M | $-9.45M | $-8.14M | $-8.71M | $-10.52M | $-14.08M | $-14.80M | $-23.76M | $-23.64M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.57M | $-26.95M | $-24.51M | $-21.42M | $-13.11M | $2.86M | $-2.27M | $-12.58M | $-20.23M | $-8.29M | $-27.32M | $-27.44M |
High Forecast | $-14.58M | $-14.61M | $-12.70M | $-12.73M | $-11.04M | $-9.45M | $-8.14M | $-8.71M | $-10.52M | $-13.71M | $-14.80M | $-23.76M | $-17.84M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.57M | $-26.95M | $-24.51M | $-21.42M | $-13.11M | $3.43M | $-2.27M | $-12.58M | $-20.23M | $-6.63M | $-27.32M | $-27.44M |
Low Forecast | $-14.58M | $-14.61M | $-12.70M | $-12.73M | $-11.04M | $-9.45M | $-8.14M | $-8.71M | $-10.52M | $-14.70M | $-14.80M | $-23.76M | $-30.63M | $-28.26M | $-28.60M | $-29.22M | $-29.11M | $-26.55M | $-25.57M | $-26.95M | $-24.51M | $-21.42M | $-13.11M | $2.29M | $-2.27M | $-12.58M | $-20.23M | $-9.95M | $-27.32M | $-27.44M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.26% | 0.52% | 0.67% | 0.62% | 0.95% | 0.80% | 1.43% | 0.49% | 6.54% | 0.47% | 0.61% | 1.00% | 0.48% | 0.40% |
Affimed SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 8 | 8 | 12 | 7 | 12 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.85M | $8.57M | $8.09M | $8.37M | $7.04M | $7.45M | $6.84M | $5.44M | $4.49M | $4.13M | $3.46M | $2.61M | $3.52M | $2.70M | $2.79M |
Avg Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $386.04K | $386.04K | $386.04K | $386.04K | $1.74M | $1.78M | $1.23M | $488.01K | $1.76M | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $10.97M | $9.56M | $10.21M | $9.59M | $9.08M | $17.69M | $9.36M | $5.54M | $3.52M | $3.29M | $3.94M |
High Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $386.04K | $386.04K | $386.04K | $386.04K | $1.74M | $2.84M | $1.23M | $488.01K | $2.79M | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $10.97M | $9.56M | $10.21M | $9.59M | $10.90M | $17.69M | $9.36M | $5.54M | $4.23M | $3.29M | $3.94M |
Low Forecast | $161.20K | $161.47K | $161.74K | $162.00K | $386.04K | $386.04K | $386.04K | $386.04K | $1.74M | $705.88K | $1.23M | $488.01K | $684.36K | $2.05M | $4.95M | $6.56M | $7.36M | $6.70M | $9.39M | $10.97M | $9.56M | $10.21M | $9.59M | $7.27M | $17.69M | $9.36M | $5.54M | $2.82M | $3.29M | $3.94M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.16% | 1.21% | 0.89% | 0.64% | 0.78% | 0.67% | 0.57% | 0.49% | 0.23% | 0.37% | 0.47% | 1.00% | 0.82% | 0.71% |
Affimed EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 11 | 8 | 8 | 12 | 7 | 12 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.21 | $-0.26 | $-0.09 | $-0.12 | $-0.14 | $-0.29 | $-0.14 | $-0.16 | $0.01 | $-0.13 | $-0.07 | $-0.16 | $-0.11 | $-0.17 | $-0.17 |
Avg Forecast | $-0.95 | $-0.96 | $-0.83 | $-0.83 | $-0.72 | $-0.62 | $-0.53 | $-0.57 | $-0.69 | $-0.92 | $-0.97 | $-1.55 | $-1.55 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
High Forecast | $-0.95 | $-0.96 | $-0.83 | $-0.83 | $-0.72 | $-0.62 | $-0.53 | $-0.57 | $-0.69 | $-0.90 | $-0.97 | $-1.55 | $-1.17 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
Low Forecast | $-0.95 | $-0.96 | $-0.83 | $-0.83 | $-0.72 | $-0.62 | $-0.53 | $-0.57 | $-0.69 | $-0.96 | $-0.97 | $-1.55 | $-2.00 | $-1.85 | $-1.87 | $-1.91 | $-1.90 | $-1.74 | $-1.67 | $-1.76 | $-1.60 | $-1.40 | $-0.86 | $-1.00 | $-0.15 | $-0.82 | $-1.32 | $-1.29 | $-1.79 | $-1.79 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.11% | 0.14% | 0.05% | 0.07% | 0.08% | 0.18% | 0.10% | 0.19% | -0.01% | 0.86% | 0.09% | 0.12% | 0.09% | 0.10% | 0.09% |
Affimed Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
ADCT | ADC Therapeutics SA | $3.02 | $9.33 | 208.94% | Buy |
PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
AGEN | Agenus | $4.06 | $8.00 | 97.04% | Hold |
MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
CRVS | Corvus Pharmaceuticals | $9.02 | $9.50 | 5.32% | Buy |
EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
AFMD Forecast FAQ
Is Affimed a good buy?
Yes, according to 5 Wall Street analysts, Affimed (AFMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AFMD's total ratings.
What is AFMD's price target?
Affimed (AFMD) average price target is $7.5 with a range of $5 to $10, implying a 129.36% from its last price of $3.27. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Affimed stock go up soon?
According to Wall Street analysts' prediction for AFMD stock, the company can go up by 129.36% (from the last price of $3.27 to the average price target of $7.5), up by 205.81% based on the highest stock price target, and up by 52.91% based on the lowest stock price target.
Can Affimed stock reach $5?
AFMD's average twelve months analyst stock price target of $7.5 supports the claim that Affimed can reach $5 in the near future.
What are Affimed's analysts' financial forecasts?
Affimed's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.45M (high $1.45M, low $1.45M), average EBITDA is $-1.451M (high $-1.451M, low $-1.451M), average net income is $-37.339M (high $-37.339M, low $-37.339M), average SG&A $1.54M (high $1.54M, low $1.54M), and average EPS is $-2.44 (high $-2.44, low $-2.44). AFMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $607.42K (high $607.42K, low $607.42K), average EBITDA is $-607K (high $-607K, low $-607K), average net income is $-54.611M (high $-54.611M, low $-54.611M), average SG&A $646.41K (high $646.41K, low $646.41K), and average EPS is $-3.569 (high $-3.569, low $-3.569).
Did the AFMD's actual financial results beat the analysts' financial forecasts?
Based on Affimed's last annual report (Dec 2022), the company's revenue was $41.35M, beating the average analysts forecast of $32.35M by 27.84%. Apple's EBITDA was $-86.637M, beating the average prediction of $-32.346M by 167.84%. The company's net income was $-86.004M, missing the average estimation of $-108M by -20.50%. Apple's SG&A was $32.08M, missing the average forecast of $34.42M by -6.82%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-7.07 by -91.51%. In terms of the last quarterly report (Mar 2023), Affimed's revenue was $4.51M, missing the average analysts' forecast of $6.16M by -26.82%. The company's EBITDA was $-30.662M, beating the average prediction of $-6.163M by 397.50%. Affimed's net income was $-31.983M, beating the average estimation of $-29.218M by 9.46%. The company's SG&A was $6.85M, beating the average forecast of $6.56M by 4.44%. Lastly, the company's EPS was $-0.21, missing the average prediction of $-1.91 by -89.00%